TAVR | tctmd.com

News Daily News

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

By L.A. McKeown

October 08, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

By Yael L. Maxwell

October 15, 2015

News Industry News

Edwards SAPIEN 3 Valve Demonstrates High Survival And Low Stroke Rate At 1 Year

October 15, 2015

News Conference News TCT 2015

CoreValve Extreme Risk Pivotal Trial: Improved Benefits Confirmed After 3 Years

October 12, 2015

News Daily News

RenalGuard Protects TAVR Patients Against AKI Better Than Does Standard Saline

September 22, 2015

News Industry News

Favorable Results At One Year With Newest Generation Of Balloon-Expandable Transcatheter Aortic Valve In High-Risk And Inoperable Patients With Aortic Stenosis

October 15, 2015

News Conference News TCT 2015

MISTRAL-C: Cerebral Protection in TAVR May Reduce New Lesions

October 14, 2015

News Conference News TCT 2015

Asian TAVR Registry Shows Good Procedural and Clinical Results

October 11, 2015

News Daily News

In the Early Days of TAVR, No Mortality Penalty for Patients Treated Outside of Trial Centers

October 01, 2015

News Daily News

Post-TAVR Myocardial Injury Linked to Mortality

By Caitlin E. Cox

November 02, 2015

Subscribe to TAVR

Advertisement

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Edwards SAPIEN 3 Valve Demonstrates High Survival And Low Stroke Rate At 1 Year

CoreValve Extreme Risk Pivotal Trial: Improved Benefits Confirmed After 3 Years

RenalGuard Protects TAVR Patients Against AKI Better Than Does Standard Saline

Favorable Results At One Year With Newest Generation Of Balloon-Expandable Transcatheter Aortic Valve In High-Risk And Inoperable Patients With Aortic Stenosis

MISTRAL-C: Cerebral Protection in TAVR May Reduce New Lesions

Asian TAVR Registry Shows Good Procedural and Clinical Results

In the Early Days of TAVR, No Mortality Penalty for Patients Treated Outside of Trial Centers

Post-TAVR Myocardial Injury Linked to Mortality

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content